TGFB1 and systemic lupus erythematosus: For example, in SLE patients, the therapeutic effect of allogeneic MSC application was accompanied by an upregulation of Tregs and downregulation of Th17 cells, which was dependent on sHLA-G and TGF-β1, or PGE2 action, respectively [55,56].